Research shines new light on role of AKI in development of lung injury

NewsGuard 100/100 Score

Acute kidney injury (AKI) is sudden kidney failure or damage lasting from a few hours to several days. During this time, the kidney's ability to maintain a proper balance of bodily fluids is compromised and causes a buildup of waste products in the blood. There are several causes of AKI including decreased blood flow to the kidneys, direct kidney damage, and blockage of the urinary tract. The mortality rate for AKI is relatively high and is often exasperated by complications with the respiratory system. Unfortunately, the relationship between lung injury and AKI is not completely understood.

To find a connection between acute lung injury (ALI) and AKI, researchers from Kumamoto University in Japan developed a bilateral nephrectomy (BNx)-induced AKI rat model. Based on previous research, they focused mainly on indoxyl sulfate (IS), a chemical that contributes to kidney disease that is normally excreted in urine but remains in the circulatory system of those with kidney disease. The experiments included three subject types, sham-operated (sham), BNx, and BNx rats that were given the orally administered intestinal sorbent AST-120 (BNx+AST-120), which decreases uremic toxins like IS.

The researchers had two goals, to see if IS affected aquaporin 5 (AQP-5), a protein with the main function of transporting water across lung cell membranes, and to determine if IS plays a role in the development of ALI during instances of kidney injury or disease. Their results showed that serum IS levels and IS organ accumulation (lungs, liver, heart, intestine) 48 hours after surgery was significantly higher for BNx rats than both the sham and BNx+AST-120 rats. Histological analyses of lung tissues revealed a significant reduction of interstitial tissue thickening in the BNx+AST-120 rats compared to the BNx rats. Furthermore, Western blot and immunohistochemical analyses helped confirm that the BNx+AST-120 rats had AQP-5 levels similar to the sham rat.

"Our work confirms that acute kidney damage results in an accumulation of IS in lung tissue and may cause acute lung injury through renopulmonary crosstalk," said lead researcher Dr. Hideyuki Saito. "In other words, IS accumulation acts to dysregulate the expression of salt and water channels in the lungs leading to thickened tissue and lung damage. Fortunately, we also found that oral treatment with the intestinal sorbent AST-120 had the positive effect of returning interstitial lung tissue to a relatively normal thickness by decreasing production and pulmonary accumulation of IS."

One limitation of this study was the low number of test subjects; the experimental procedure only used three rats for each of the three surgical variables. However, future studies are planned to clarify mechanisms involved in the dysregulation of AQP-5 by IS, which may further support the results of this study.

The findings of this research shine a new light on the role that AKI plays in the development of ALI, i.e., renopulmonary crosstalk, and may provide insight into new therapeutic approaches. The full research article may be found on the International Journal of Molecular Sciences website.

Source: Kumamoto University

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Kidney-CHAMP framework provides equitable access and overcomes barriers to kidney disease care